当前位置:首页>产品中心>单抗/多抗>Anti-Human CXCL10/IP-10/CRG-2 Reference Antibody|抗人CXCL10/IP-10/CRG-2参考抗体(靶标:人CXC趋化因子配体10(干扰素诱导蛋白10))

Anti-Human CXCL10/IP-10/CRG-2 Reference Antibody|抗人CXCL10/IP-10/CRG-2参考抗体(靶标:人CXC趋化因子配体10(干扰素诱导蛋白10))

  • 货号:RB9THY524016
  • 价格:面议
  • 点击:417
   一键复制产品信息 复制成功!

产品介绍

产品参数

形态Liquid
宿主种属Human
克隆性Monoclonal
抗体亚型IgG1-kappa
纯度>95% as determined by SDS-PAGE.
纯化方式Protein A/G purified from cell culture supernatant.
浓度1 mg/ml
内毒素水平Please contact with the lab for this information.
应用ELISA, Bioactivity: FACS, Functional assay, Research in vivo
种属反应性Human
靶标Gamma-IP10, C-X-C motif chemokine 10, INP10, 10 kDa interferon gamma-induced protein, Small-inducible cytokine B10, SCYB10, IP-10, CXCL10
储存缓冲液0.01M PBS, pH 7.4.
稳定性和储存Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
表达系统Mammalian Cells
登录号P02778
背景信息Eldelumab (alternative identifier BMS-936557) is a fully human monoclonal antibody (type IgG1 kappa) that targets chemokine (CXC motif) ligand 10 (CXCL10)/Interferon-γ-inducible protein-10 (IP-10). This drug was developed by Bristol-Myers Squibb and Medarex and designed for the treatment of Crohn's disease and ulcerative colitis. To date, eldelumab has been investigated as an induction and maintenance therapy in active Crohn's disease, and its induction treatment demonstrated trends towards clinical and endoscopic efficacy with no new safety signal in a phase IIa study. Meanwhile, inhibiting IP-10 activity through the use of the monoclonal antibody, eldelumab, demonstrated efficacy in patients who achieved high serum concentrations in this phase II, randomized, controlled, proof-of-concept study of moderate-to-severe ulcerative colitis.
• The human gene encoding SCYB9B, a putative novel CXC chemokine, maps to human chromosome 4q21 like the closely related genes for MIG (SCYB9) and INP10 (SCYB10)., PMID:9730616
别名BMS-936557, MDX-1100, 946414-98-8
种属Human
备注For research use only. Not suitable for clinical or therapeutic use.
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 616
Anti-Disitamab Neutralizing Recombinant Antibody |抗迪西妥单抗中和重组抗体(靶标:迪西妥单抗中和抗体) 808
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 845
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 731
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 660
Anti-Sacituzumab Neutralizing Recombinant Antibody |抗沙西妥珠单抗中和重组抗体(靶标:沙西妥珠单抗中和抗体) 667
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 383
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 654
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 738
Anti-Cetuximab Neutralizing Recombinant Antibody |抗西妥昔单抗中和重组抗体(靶标:西妥昔单抗中和抗体) 709
Anti-Human CD42b/GP1BA Recombinant Antibody|抗人CD42b/GP1BA重组抗体(靶标:人血小板糖蛋白Ibα链/CD42b) 841
Anti-Human JMJD1C Polyclonal Antibody|抗人JMJD1C多克隆抗体(靶标:人Jumonji结构域含蛋白1C) 675
Anti-Human ITGB6 Polyclonal Antibody|抗人ITGB6多克隆抗体(靶标:人整合素β6亚基) 866
Anti-Mouse IL33 Recombinant Antibody |抗小鼠IL33重组抗体(靶标:小鼠白细胞介素33) 602
Anti-Mouse CD1d/CD1.1 Recombinant Antibody|抗小鼠CD1d/CD1.1重组抗体(靶标:小鼠CD1d分子) 795
Anti-Mouse α5β1 (ITGA5 & ITGB1) Recombinant Antibody|抗小鼠α5β1(ITGA5和ITGB1)重组抗体(靶标:小鼠整合素α5β1复合物) 793
Anti-Mouse VEGFA Recombinant Antibody|抗小鼠VEGFA重组抗体(靶标:小鼠血管内皮生长因子A) 494
总计 33037 个记录,共 1652 页,当前第 1652 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00